Zoliflodacin is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.
- Mechanism
- Curator reviewed · 4 references
Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic that inhibits bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), which are required for DNA synthesis. Unlike other topoisomerase inhibitors, zoliflodacin binds within the cleaved DNA-gyrase complex to block re-ligation and interacts with conserved amino acids in the gyrase B subunit. This distinct mode of action targeting the gyrase B subunit allows for activity against strains resistant to other classes of antimicrobials, including fluoroquinolones.
- Primary indication
- Zoliflodacin is indicated for the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older and weighing at least 35 kg.Curator reviewed · 1 structured indication
- Formula / weight
- C22H22FN5O7 · 487.444 g/mol (avg)
- First approval
- United States, 2026
- Code names
- AZD-0914 · ETX-0914
- Brand names
Resolves to
ZSWMIFNWDQEXDT-ZESJGQACSA-NSMILES[H][C@]12[C@H](C)O[C@H](C)CN1C1=C(CC22C(=O)NC(=O)NC2=O)C=C2C(ON=C2N2[C@@H](C)COC2=O)=C1FWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Zoliflodacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account